Get the Stockscreener App
9.16
2.35%
0.21
After Hours:
9.16
Adma Biologics Inc stock is traded at $9.16, with a volume of 2.62M.
It is up +2.35% in the last 24 hours and up +14.93% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$8.95
Open:
$8.915
24h Volume:
2.62M
Relative Volume:
0.47
Market Cap:
$2.12B
Revenue:
$509.86M
Net Income/Loss:
$165.35M
P/E Ratio:
13.51
EPS:
0.6779
Net Cash Flow:
$107.55M
1W Performance:
+9.44%
1M Performance:
+14.93%
6M Performance:
-50.05%
1Y Performance:
-49.89%
1-Day Range:
$8.84
$9.17
1-Week Range:
$8.29
$9.17
52-Week Range:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.16 | 1.94B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NNOX - GlobeNewswire Inc.
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ADMA Biologics, Inc. Class Action Lawsuit Seeks Recovery - GlobeNewswire
ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline - PR Newswire
ADMA BIOLOGICS, INC. INVESTORS WITH LOSSES HAVE UNTIL - GlobeNewswire
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
ADMA Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - marketscreener.com
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - Stocktwits
Trading Systems Reacting to (ADMA) Volatility - Stock Traders Daily
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential - GlobeNewswire
ADMA Biologics, Inc. (ADMA) Investigation: Bronstein, Gewirtz & G - The National Law Review
$ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action - TradingView
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo! Finance Canada
ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA - Business Wire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmADMA - TMX Newsfile
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Investor Announcement: ADMA Biologics Investors are Notified to Contact BFA Law about the Pending Securities Fraud Class Action to Recover Stock Losses - GlobeNewswire
ADMA Biologics, Inc.(NasdaqGM: ADMA) added to Russell 2000 Growth-Defensive Index - marketscreener.com
ADMA Biologics, Inc. (ADMA) Class Action Lawsuit Seeks Recovery for Investors; August 10, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA Biologics Faces Securities Fraud Class Action Lawsuit - Intellectia AI
ADMA Biologics, Inc. Actuals & Estimates (NASDAQ:ADMA) - TradingView
Kessler Topaz Meltzer & Check, LLP - GlobeNewswire Inc.
Did You Lose Money on ADMA Biologics, Inc. (ADMA)? Levi & Korsinsky Urges Investors to Act Before August 10, 2026 - ACCESS Newswire
Levi & Korsinsky Urges ADMA Biologics, Inc. (ADMA) Shareholders to Act Before Lead Plaintiff Deadline August 10, 2026 - ACCESS Newswire
ADMA Biologics, Inc. Actuals & Estimates (BX:ADMA) - TradingView
Levi & Korsinsky Notifies ADMA Biologics, Inc. (ADMA) Shareholders of Class Action Lawsuit and August 10, 2026 Deadline - ACCESS Newswire
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - PR Newswire
ADMA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ADMA Biologics, Inc. Investors - GlobeNewswire Inc.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Keene Sentinel
Class Action Lawsuit Filed Against ADMA Biologics, Inc. (ADMA)Recover LossesContact Levi & Korsinsky Before August 10, 2026 - ACCESS Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders - GlobeNewswire
DEADLINE ALERT for VIA, Z, and ADMA: The Law Offices of - GlobeNewswire
ADMA Shareholder Alert: ADMA Biologics, Inc. Securities - GlobeNewswire
ADMA Biologics, Inc. (ADMA) Investors: August 10, 2026, Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
ADMA Biologics Inc (ADMA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
ADMA Biologics, Inc. Actuals & Estimates (BOATS:ADMA) - TradingView
Price to earnings forward of ADMA Biologics Inc – NASDAQ:ADMA - TradingView
Enterprise value to revenue forward of ADMA Biologics Inc – NASDAQ:ADMA - TradingView
What Are the Allegations Against ADMA Biologics - Kavout | AI
ADMA LAWSUIT ALERT: Levi & Korsinsky Notifies ADMA Biologics, Inc. InvestorsLead Plaintiff Deadline August 10, 2026 - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmADMA - ACCESS Newswire
Contact Levi & Korsinsky by August 10, 2026 to Join Class Action Against ADMA Biologics, Inc. (ADMA) - ACCESS Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds ADMA Biologics, Inc. (ADMA) Investors of August 10, 2026 Deadline - ACCESS Newswire
Enterprise value to EBITDA forward of ADMA Biologics Inc – NASDAQ:ADMA - TradingView
Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Before August 10, 2026 to Join Class Action - ACCESS Newswire
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel ... - Caledonian Record
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director |
May 12 '26 |
Buy |
8.01 |
12,500 |
100,125 |
513,884 |
| Grossman Jerrold B | Director |
May 11 '26 |
Buy |
8.01 |
12,500 |
100,125 |
501,384 |
| Guiheen Lawrence P. | Director |
Mar 13 '26 |
Option Exercise |
3.66 |
30,000 |
109,800 |
135,520 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):